Current understanding of rheumatoid arthritis therapy (Q37987351)

26 August 2017

Current understanding of rheumatoid arthritis therapy (English)

1 reference

26 August 2017

1 reference

Inés Colmegna

1

1 reference

26 August 2017

Brent R Ohata

series ordinal

2

1 reference

26 August 2017

Henri A Menard

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

22 February 2012

1 reference

Clinical Pharmacology & Therapeutics

26 August 2017

1 reference

26 August 2017

91

1 reference

26 August 2017

607-620

1 reference

26 August 2017

4

1 reference

T cells in rheumatoid arthritis

26 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

The burden of illness of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Improving the routine management of rheumatoid arthritis: the value of tight control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Induction of immune tolerance in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Cytokines in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

(Re)defining biopharmaceutical

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

TNF receptor subtype signalling: differences and cellular consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

TNF receptor 2 pathway: drug target for autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Immune-mediated pathways in chronic inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Biologicals for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Interleukin 6 plays a key role in the development of antigen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

The pro- and anti-inflammatory properties of the cytokine interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

The role of vascular endothelial growth factor in pathological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Interleukin-1beta (IL-1beta) processing pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

IL-1 pathways in inflammation and human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

The IL-17 pathway as a major therapeutic target in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Mast cells express IL-17A in rheumatoid arthritis synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Interleukin-23: a key cytokine in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Interleukin-33 biology with potential insights into human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Transfer of rheumatoid arthritis into severe combined immunodeficient mice. The pathogenetic implications of T cell populations oligoclonally expanding in the rheumatoid joints

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

T-cell-targeted therapies in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Abatacept treatment for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Therapeutic targeting of B cells for rheumatic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Targeting the B cell in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

7 January 2021

Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

7 January 2021

Infliximab: 12 years of experience

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

7 January 2021

Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

7 January 2021

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

7 January 2021

Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

7 January 2021

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

7 January 2021

T cell activation in rheumatoid synovium is B cell dependent

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

7 January 2021

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.325

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.325

1 reference

26 August 2017

1 reference